{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:40Z","timestamp":1790474140167,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"OPRAS","award":["1-2015"],"award-info":[{"award-number":["1-2015"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (<jats:styled-content style=\"fixed-case\">MPM<\/jats:styled-content>) in France and to analyze its associations with socioeconomic deprivation, population density, and management outcomes. A national hospital database was used to extract incident <jats:styled-content style=\"fixed-case\">MPM<\/jats:styled-content> patients in years 2011 and 2012. Cox models were used to analyze 1\u2010 and 2\u2010year survival according to sex, age, co\u2010morbidities, management, population\u2010density index, and social deprivation index. The analysis included 1,890 patients (76% men; age: 73.6\u00a0\u00b1\u00a010.0\u00a0years; 84% with significant co\u2010morbidities; 57% living in urban zones; 53% in highly underprivileged areas). Only 1% underwent curative surgical procedure; 65% received at least one chemotherapy cycle, 72% of them with at least one pemetrexed and\/or bevacizumab administration. One\u2010 and 2\u2010year survival rates were 64% and 48%, respectively. Median survival was 14.9 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 13.7\u201315.7) months. The mean cost per patient was 27,624\u00a0\u00b1\u00a017,263 euros (31% representing pemetrexed and bevacizumab costs). Multivariate analyses retained men, age &gt;70\u00a0years, chronic renal failure, chronic respiratory failure, and never receiving pemetrexed as factors of poor prognosis. After adjusting the analysis to age, sex, and co\u2010morbidities, living in rural\/semi\u2010rural area was associated with better 2\u2010year survival (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>: 0.83 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.73\u20130.94]; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01); social deprivation index was not significantly associated with survival. With approximately 1,000 new cases per year in France, <jats:styled-content style=\"fixed-case\">MPM<\/jats:styled-content>s represents a significant national health care burden. Co\u2010morbidities, sex, age, and living place appear to be significant factors of prognosis.<\/jats:p>","DOI":"10.1002\/cam4.1378","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T08:42:45Z","timestamp":1519634565000},"page":"1102-1109","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"first","affiliation":[{"name":"GRC OncoThoParisEst Service de Pneumologie, CHI Cr\u00e9teil UPEC  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Baptiste","family":"Assi\u00e9","sequence":"additional","affiliation":[{"name":"GRC OncoThoParisEst Service de Pneumologie, CHI Cr\u00e9teil UPEC  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Andujar","sequence":"additional","affiliation":[{"name":"Inserm U955 Institut Sant\u00e9 Travail Paris Est Service de Pneumologie et de Pathologie Professionnelle CHI Cr\u00e9teil  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Blein","sequence":"additional","affiliation":[{"name":"HEVA  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charl\u00e8ne","family":"Tournier","sequence":"additional","affiliation":[{"name":"HEVA  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vainchtock","sequence":"additional","affiliation":[{"name":"HEVA  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department University of Lille CHU Lille, CIIL, Inserm U1019  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[{"name":"GRC OncoThoParisEst Service de Pneumologie, CHI Cr\u00e9teil UPEC  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Pairon","sequence":"additional","affiliation":[{"name":"Inserm U955 Institut Sant\u00e9 Travail Paris Est Service de Pneumologie et de Pathologie Professionnelle CHI Cr\u00e9teil  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22206"},{"key":"e_1_2_7_3_1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson B. M.","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"e_1_2_7_4_1","first-page":"51","article-title":"The French mesothelioma network from 1998 to 2013","volume":"2014","author":"Galateau\u2010Salle F.","year":"2014","journal-title":"Ann. Pathol."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203744"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.09.023"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.08.019"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1881-x"},{"key":"e_1_2_7_9_1","first-page":"1","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up","volume":"00","author":"Baas P.","year":"2015","journal-title":"Ann. Oncol."},{"key":"e_1_2_7_10_1","first-page":"2493","article-title":"Randomized trials of systemic medically\u2010treated malignant mesothelioma: a systematic review","volume":"35","author":"Blomberg C.","year":"2015","journal-title":"Anticancer Res."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.11.026"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/jnci\/djm257","article-title":"In Australia, patients and government at odds over mesothelioma treatment costs","volume":"99","author":"Burkitt V.","year":"2007","journal-title":"J. Natl. Cancer Insti."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00209.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1753-3"},{"key":"e_1_2_7_16_1","volume-title":"International classification of diseases 10th revision","author":"World Health Organization","year":"2010"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318275b346"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.723"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.005"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.478"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.312"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.245"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.12.002"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000064"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.03.011"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8401"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1903e"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00153611"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182798"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02925.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-013-0528-6"},{"key":"e_1_2_7_34_1","first-page":"66","article-title":"Estimation des parts attribuables de cancers aux expositions professionnelles \u00e0 l'amiante en France: utilisation des matrices d\u00e9velopp\u00e9es dans le cadre du programme Matg\u00e9n\u00e9","author":"Gilg Soit Ilg A.","year":"2015","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1371.042"},{"key":"e_1_2_7_36_1","unstructured":"FIVA annual rapport 2016.www.fiva.fr\/fiva-adm\/rapports.php"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T05:54:59Z","timestamp":1723096499000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/cam4.1378"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1378","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"2017-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}